摘要
目的 探讨黄芪抗肝纤维化的作用与转化生长因子 β1(TGFβ1)及干扰素γ(IFN γ)的关系。方法 分别测定慢性肝炎黄芪治疗前后血清TGFβ1,透明质酸 (HA)及外周血单个核细胞 (PBMC)产生IFN γ的变化。结果 慢性乙型肝炎血清TGFβ1,HA ,PBMC产生IFN γ的含量分别为 (4 2 8.85± 117.5 3)mg/L ,(35 6 .77± 78.43) μg/L ,(12 .3± 5 .7) μg/L ,黄芪治疗后分别为 (2 2 2 .6 9± 85 .73)mg/L(P <0 .0 5 ) ,(179.2 3± 5 8.43) μg/L(P <0 .0 1) ,(2 2 .6± 8.7) μg/L(P <0 .0 5 ) ,治疗前后TGFβ1,HA均高于对照组 ,治疗前PBMC产生IFN γ含量低于对照组 (P <0 .0 5 )。结论 黄芪具有抗肝纤维化作用 ,其机制可能与调节患者TGFβ1,IFN γ含量有关。
Objective To investigate relationship between antifibrotic effect of astragalus membranaceus(AM)on liver fibrosis and transforming growth factor β 1(TGF β 1)or interferon-gamma(IFN-γ) Methods Serum TGF β 1, hyaluronic acid(HA)and IFN-γ of peripheral blood monoclear cells(PBMCs)in patients with chronic hepatitis B(CHB)were tested respectively Results Serum TGF β 1, HA, IFN-γ levels were (428.85±117.53)mg/L,(356.77±78.43)μg/L,(12.3±5.77)μg/L respectively and after treatment with AM were (222.69±85.73)mg/L( P <0.05), (179.23±58.43)μg/L( P <0.01),(22.6±9.7)μg/L( P <0.05) Serum TGF β 1, HA levels in patients with CHB before or after treatment with AM were higher than in control group significantly, IFN-γ level of PBMSc in patients with CHB before treatment was lower than in control group Conclusion AM can treat liver fibrosis and its mechanism might be relative to regulating TGF β 1,IFN-γ level of CHB
出处
《临床军医杂志》
CAS
2000年第3期22-23,共2页
Clinical Journal of Medical Officers
关键词
黄芪
转化生长因子Β
干扰素Γ
肝纤维化
interferon-γ
transforming growth factor β 1
astragalus membranaceus
liver fibrosis
